Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1

Conditions

Breast Neoplasms 987Neoplasms 796Carcinoma, Non-Small-Cell Lung 763Prostatic Neoplasms 588Colorectal Neoplasms 484Lung Neoplasms 468Neoplasm Metastasis 413Multiple Myeloma 382Leukemia, Myeloid, Acute 377Ovarian Neoplasms 316Pancreatic Neoplasms 297Melanoma 278Squamous Cell Carcinoma of Head and Neck 258Recurrence 244Carcinoma, Hepatocellular 240Brain Neoplasms 226Glioblastoma 217Triple Negative Breast Neoplasms 204Carcinoma, Renal Cell 200Head and Neck Neoplasms 198Lymphoma 193Stomach Neoplasms 190Precursor Cell Lymphoblastic Leukemia-Lymphoma 189Sarcoma 172Glioma 171Uterine Cervical Neoplasms 169Lymphoma, Non-Hodgkin 169Endometrial Neoplasms 169Lymphoma, Large B-Cell, Diffuse 166Urinary Bladder Neoplasms 160

Interventions

folfirinox 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1HhAntag691 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Basal Cell × 90 days × Clear all
NCT00833417 2026-05-11

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Genentech, Inc.

Phase 2 Completed
104 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Neoplasms, Basal Cell

NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡